Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - sotalol hydrochloride, quantity: 160 mg - tablet, uncoated - excipient ingredients: maize starch; sodium starch glycollate; purified talc; magnesium stearate; calcium hydrogen phosphate; povidone - for the prevention and treatment of supraventricular and ventricular arrhythmias.

United States - English - NLM (National Library of Medicine)

bionpharma inc. - fluvoxamine maleate (unii: 5lgn83g74v) (fluvoxamine - unii:o4l1xpo44w) - fluvoxamine maleate extended-release capsules are indicated for the treatment of obsessive compulsive disorder (ocd), as defined in the dsm-iv. obsessive compulsive disorder is characterized by recurrent and persistent ideas, thoughts, impulses, or images (obsessions) that are ego-dystonic and/or repetitive, purposeful, and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable. the obsessions or compulsions cause marked distress, are time-consuming, or significantly interfere with social or occupational functioning. the efficacy of fluvoxamine maleate extended-release capsules was demonstrated in one 12-week trial in adults with fluvoxamine maleate extended-release capsules as well as in two 10-week trials in adults and in one 10-week trial in children and adolescents (ages 8 to 17 years) with immediate-release fluvoxamine tablets in outpatients with the diagnosis of ocd as defined in dsm-iv or dsm-iii-r (see  clinical studies  [14.1,